Pfizer Wins Us Lipitor Patent Case
Reuters reports that generic drug manufacturer Ranbaxy has failed inward its examine to piece of job out Pfizer’s the States patents inward its LIPITOR anti-cholesterol drug invalidated. The determination past times a the States federal guess agency that Ranbaxy cannot launch a generic version of LIPITOR at present. As a result, its portion cost has dropped past times near 9%, spell the portion prices of big pharmaceutical companies, including around that were non involved inward the litigation, bring risen. Ranbaxy bring announced that it intends to appeal.
notes that this upshot mirrors Pumfrey J’s decision to uphold the validity of the U.K. patents for LIPITOR held past times Pfizer inward October.
Comments
Post a Comment